Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.44 |
| ▸ | CA1 | P00915 | 17/20 | 0.44 |
| ▸ | CA9 | Q16790 | 12/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA3 | P07451 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | CA6 | P23280 | 2/20 | 0.36 |
| ▸ | CA5A | P35218 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL575713 | 0.94 | CA2 (0.44) | CA2CA1CA9KDM4EUSP2 | |
| SCHEMBL12737572 | 0.93 | CA2 (0.41) | CA2CA1CA9KDM4EUSP2 | |
| SCHEMBL8398329 | 0.92 | CA2 (0.46) | CA2CA1CA9KDM4EUSP2 | |
| SCHEMBL2735589 | 0.92 | CA2 (0.46) | CA2CA1CA9KDM4EUSP2 | |
| SCHEMBL4952312 | 0.92 | CA2 (0.46) | CA2CA1CA9KDM4EUSP2 | |
| SCHEMBL23291930 | 0.92 | CA2 (0.46) | CA2CA1CA9KDM4EUSP2 | |
| SCHEMBL14779178 | 0.92 | CA2 (0.46) | CA2CA1CA9KDM4EUSP2 | |
| SCHEMBL3375426 | 0.89 | CA2 (0.39) | CA2CA1CA9KDM4EUSP2 | |
| SCHEMBL10470061 | 0.89 | USP2 (0.58) | CA2CA1CA9KDM4EUSP2 | |
| SCHEMBL18889097 | 0.89 | CA2 (0.39) | CA2CA1CA9KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4676930-A1 | METHODS FOR PREPARING PYRROLIZIDINE COMPOUNDS | Frontier Medicines Corporation (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250066388-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2025-02-27 | — | — | US | disclosed |
| EP-3642248-B1 | BIARYL PHENOXY GROUP IV TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-118660947-A | Surface treatment agent, coating liquid, article, and method for producing article | ＡＧＣ株式会社 | 2024-09-17 | — | — | CN | disclosed |
| WO-2024186680-A1 | METHODS FOR PREPARING PYRROLIZIDINE COMPOUNDS | FRONTIER MEDICINES CORPORATION (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240297344-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-05 | — | — | US | disclosed |
| US-11964990-B2 | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors | ABBVIE INC. (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2023153450-A1 | SURFACE TREATMENT AGENT, COATING LIQUID, ARTICLE, AND METHOD FOR PRODUCING ARTICLE | ＡＧＣ株式会社 | 2023-08-17 | — | — | WO | disclosed |
| US-20230234971-A1 | 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors | ABBVIE INC. (US) | 2023-07-27 | — | — | US | disclosed |
| EP-1660443-B1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | SCHERING CORP (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-2031689-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-03-04 | — | — | EP | disclosed |
| US-20080311478-A1 | Lithium Secondary Battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1892789-A1 | LITHIUM SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2008-02-27 | — | — | EP | disclosed |
| EP-1313747-B1 | METHOD FOR PRODUCING ALKYL-BRIDGED LIGAND SYSTEMS AND TRANSITION METAL COMPOUNDS | BASELL POLYOLEFINE GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| WO-2005016876-A2 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | SCHERING CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-6784305-B2 | DERIVATIVES OF ZIRCONOCENE DICHLORIDE IN WHICH THE TWO SUBSTITUTED INDENYL GROUPS ARE JOINED TO ONE ANOTHER VIA A BRIDGE CAN, OWING TO THEIR CONFORMATIONAL RIGIDITY, BE USED AS CATALYSTS FOR THE STEREOSPECIFIC POLYMERIZATION OF OLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2004-08-31 | — | — | US | disclosed |
| US-20030199703-A1 | Method for producing alkyl-bridged ligand systems and transition metal compounds | EQUISTAR CHEMICALS, LP | 2003-10-23 | — | — | US | disclosed |
| EP-1313747-A1 | METHOD FOR PRODUCING ALKYL-BRIDGED LIGAND SYSTEMS AND TRANSITION METAL COMPOUNDS | Basell Polypropylen GmbH (DE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002018397-A1 | METHOD FOR PRODUCING ALKYL-BRIDGED LIGAND SYSTEMS AND TRANSITION METAL COMPOUNDS | BASELL POLYPROPYLEN GMBH (DE) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L2, BCL2L1 | CA2 185/4885CA1 1673/4885CA9 2946/4885 |
| US-20250066388-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L1, BCL2L2 | CA2 1172/4885CA1 2200/4885CA9 4227/4885 |
| US-20030199703-A1 | Method for producing alkyl-bridged ligand systems and transition metal compounds | ABL1, ICMT, ORAI2 | CA2 1949/4885CA1 3370/4885CA9 1697/4885 |
| US-20230234971-A1 | 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors | BCL9L, BCL2L1, BCL2L2 | CA2 1172/4885CA1 2200/4885CA9 4227/4885 |
| US-11964990-B2 | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors | BCL9L, BCL2L1, BCL9 | CA2 1226/4885CA1 2292/4885CA9 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.